GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Rigel Pharmaceuticals
The shares of Rigel Pharmaceuticals, a biopharmaceutical company focused on treating immune diseases, reflect the sector's binary risks. Their price trajectory depends entirely on the results of clinical trials and the commercial success of its approved drugs.
Share prices of companies in the market segment - Pharma immune
Rigel Pharmaceuticals focuses on developing small molecules to treat diseases in immunology, oncology, and hematology. We classify the company in the Pharmaceuticals (Immunology) segment, which is at the forefront of science. The chart below reflects the dynamics of this entire sector, which carries both high risks and the potential rewards of innovation.
Broad Market Index - GURU.Markets
Rigel Pharmaceuticals is a biopharmaceutical company focused on developing small-molecule drugs for the treatment of hematological and immunological diseases. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market.
Change in the price of a company, segment, and market as a whole per day
RIGL - Daily change in the company's share price Rigel Pharmaceuticals
Rigel, a biopharmaceutical company, experiences daily fluctuations that reflect the inherent volatility of the sector. Change_co measures the reaction to research data and the commercial success of its drugs. This metric is important for analyzing risks and opportunities in biotech on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
Rigel Pharmaceuticals, Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with RIGL, which focuses on immune disease treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Rigel is a biopharmaceutical company specializing in drugs for the treatment of immune diseases. Immunology is a cutting-edge but highly volatile segment of biotechnology. The chart below shows average daily fluctuations in this area, allowing you to assess Rigel's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Rigel Pharmaceuticals
Rigel is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma immune
Rigel Pharmaceuticals, Inc. is a commercial biopharmaceutical company focused on the treatment of blood diseases and cancer. This chart shows how its success in commercializing approved drugs and the results of clinical trials of new candidates influence its performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Rigel is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Rigel Pharmaceuticals
Riley, a small oil and gas company operating in the Permian Basin, is a key player in the monthly fluctuations of its performance chart, reflecting oil prices and its operating efficiency. The company's ability to effectively manage costs and increase production is key.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Rigel Pharmaceuticals focuses on immunology and hematology. Like many biotech companies, its value is driven by progress in clinical trials. The sector's performance reflects the overall risk appetite of investors in this field. The chart below provides the backdrop against which Rigel strives to transform scientific hypotheses into commercially successful drugs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Rigel Pharmaceuticals, Inc. is a commercial biotechnology company focused on developing small-molecule therapeutics for the treatment of hematological, oncological, and immune diseases. The company's future depends on sales of its approved drugs and success in R&D. The broader market chart serves as a backdrop to assess how these specific factors impacted its stock.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Rigel Pharmaceuticals
Rigel Pharmaceuticals, which focuses on drugs for immune diseases, exhibits high volatility. Its weekly share price performance reflects a sharp reaction to the publication of clinical trial results and regulatory decisions.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Rigel Pharmaceuticals, like other companies in its sector, is susceptible to the overall sentiment in the biotech sector. Regulatory news from the FDA, general trends in drug pricing, and investor risk appetite all impact everyone. The chart below allows you to compare whether RIGL stands out from the crowd thanks to its drug portfolio or moves with the market.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Rigel Pharmaceuticals, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how RIGL shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
RIGL - Market capitalization of the company Rigel Pharmaceuticals
Rigel Pharmaceuticals' market capitalization dynamics are a story of hopes and failures in the development of drugs to treat immune diseases. This biotech company's chart is a roller coaster, with each peak and trough corresponding to news of clinical trials. It reveals how Wall Street evaluates scientific risks and potential commercial success.
RIGL - Share of the company's market capitalization Rigel Pharmaceuticals within the market segment - Pharma immune
Rigel Pharmaceuticals focuses on developing small molecules for the treatment of immune and hematological diseases. Its share of its biopharmaceutical segment's market capitalization reflects the market's assessment of its scientific platform and the commercial potential of its drugs. The chart below shows the volatility of its share, typical for biotech companies.
Market capitalization of the market segment - Pharma immune
Rigel Pharmaceuticals develops small-molecule drugs for the treatment of immune and hematological diseases. The chart below shows the market capitalization of the entire immunology pharmaceutical sector. This represents an industry seeking ways to fine-tune the body's defenses.
Market capitalization of all companies included in a broad market index - GURU.Markets
Rigel Pharmaceuticals focuses on developing small molecules for the treatment of immunology and hematology diseases. The company's market capitalization is a measure of its scientific potential and pipeline of investigational drugs. Within the pharmaceutical industry as a whole, its value reflects the value investors place on innovative approaches to treating complex blood and immune diseases.
Book value capitalization of the company, segment and market as a whole
RIGL - Book value capitalization of the company Rigel Pharmaceuticals
Rigel Pharmaceuticals is built on scientific capital. The company's book value reflects its intellectual property (IP) for the approved drug Tavalisse, cash flow for clinical trials of new drugs, and laboratory equipment. The chart below shows how success in R&D and commercialization impacts the financial foundation of this biotech company.
RIGL - Share of the company's book capitalization Rigel Pharmaceuticals within the market segment - Pharma immune
Rigel Pharmaceuticals conducts drug research and development in its state-of-the-art laboratories. This scientific infrastructure is its key tangible asset. The S_BCap_Seg graph shows how its share of R&D capacity compares to other companies in the immunology sector, reflecting its scientific potential.
Market segment balance sheet capitalization - Pharma immune
Biotechnology is a world of contrasts. The graph shows the enormous factories of pharmaceutical giants. Rigel, as a development company, has a more streamlined model. Its value lies in its intellectual property, not in the scale of its production, although manufacturing drugs still requires its own physical facilities.
Book value of all companies included in the broad market index - GURU.Markets
Rigel Pharmaceuticals focuses on immune system diseases. The company's assets are not massive factories, but concentrated intellectual capital and laboratory equipment where new molecules are created. The chart shows the material resources devoted to "repairing" the most complex systems of the human body.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Rigel Pharmaceuticals
Rigel Pharma's balance sheet is primarily cash held in clinical trial accounts. The market, however, values the scientific potential of its immunology developments, not the clinical trials. The chart clearly shows how much the hope of creating a blockbuster drug can be worth compared to the company's actual assets.
Market to book capitalization ratio in a market segment - Pharma immune
Rigel Pharmaceuticals is a biotech company focused on treating immune and hematological diseases. Its main assets are patents and clinical trial results. This chart shows how its market valuation, based on the potential of its drugs, compares to its modest book value.
Market to book capitalization ratio for the market as a whole
Rigel Pharmaceuticals is a biotech company focused on developing small molecules for the treatment of immune diseases. Its core value is its scientific platform and clinical development pipeline. The chart illustrates how the market values this intangible but potentially highly valuable asset, reflected in a market capitalization that is far below book value.
Debts of the company, segment and market as a whole
RIGL - Company debts Rigel Pharmaceuticals
Rigel Pharmaceuticals, a clinical-stage biotech company, uses debt to fuel its research and development. The borrowed funds are used to finance lengthy and expensive trials of new drugs in immunology and hematology. This chart shows how the company is investing in its future product portfolio.
Market segment debts - Pharma immune
Rigel Pharmaceuticals is a biotech company focused on developing small molecules for the treatment of immune and hematological diseases. Financing expensive clinical trials often requires debt capital. This chart shows how the company's debt load relates to its current stage of development and the capital requirements for bringing its drugs to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Rigel Pharmaceuticals
For biopharmaceutical company Rigel, whose success depends on clinical trial results, debt is a way to finance development without diluting shareholder stakes. This chart illustrates the riskiness of the company's financing strategy, as its ability to service this debt is directly dependent on the future success of its drugs.
Market segment debt to market segment book capitalization - Pharma immune
Rigel Pharmaceuticals, a biotech company focused on treating immune and hematological diseases, compares its debt load to the overall market capitalization of the pharmaceutical sector. It shows how the company finances its expensive clinical research and drug commercialization, which are key to its survival and growth.
Debt to book value of all companies in the market
Rigel Pharmaceuticals is a biopharmaceutical company focused on immunology. Developing new drugs requires significant investment, and debt financing is common practice. This chart provides a general picture of the market's risk appetite. It helps assess how Rigel balances the need to fund R&D with maintaining a healthy balance sheet.
P/E of the company, segment and market as a whole
P/E - Rigel Pharmaceuticals
This chart for Rigel Pharmaceuticals illustrates the valuation of a biopharmaceutical company focused on immunology and hematology. Profitability depends on the market success of its drugs. This metric reflects investor expectations for sales growth of existing drugs and the potential for future developments in its pipeline.
P/E of the market segment - Pharma immune
Rigel Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of small-molecule therapeutics for the treatment of immune and hematological diseases. This chart reflects the average valuation in the immunological pharmaceuticals sector, where investors highly value scientific innovation and the potential of therapeutics to treat complex diseases.
P/E of the market as a whole
Rigel Pharmaceuticals focuses on developing small molecules to treat immunology and hematology diseases. The company's value depends on clinical trial success. This chart shows the overall market temperature. Comparison with it reveals how Rigel's valuation is detached from market realities and relies solely on hopes for a scientific breakthrough and drug approval.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Rigel Pharmaceuticals
For Rigel Pharmaceuticals, a biopharmaceutical company, this chart illustrates analyst expectations for future revenue, primarily from sales of its immune disease drugs. It demonstrates the market's confidence in the commercial potential of current and future drugs, allowing the stock to be assessed for future profitability.
%20P%2FE%20Rigel%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Rigel-Pharmaceuticals&v=1772513618599 "Chart of the company's future (projected) P/E Rigel Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma immune
Rigel Pharmaceuticals develops small-molecule drugs for the treatment of immunology and hematology diseases. The data presented here serves as a barometer of profitability expectations for the entire segment. Rigel's position in this context helps us understand whether the market values its research and development pipeline above or below that of similar biotech companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772513618640 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Rigel Pharmaceuticals develops drugs to treat immune diseases, and its valuation depends on research success rather than general market cycles. However, the overall risk appetite of investors, visible in this chart, influences the availability of capital for biotech companies in the development stage.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513618654 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Rigel Pharmaceuticals
Rigel Pharmaceuticals develops small-molecule drugs to treat diseases in hematology, oncology, and immunology. This graph illustrates the complex life of a biotech company: years of investment in research can be followed by a sharp increase in profits after the approval and launch of a new drug, such as their Tavalisse.
Profit of companies in the market segment - Pharma immune
Rigel Pharmaceuticals specializes in developing small molecules for the treatment of immune diseases and cancer. The pharmaceutical sector is one of the most risky and potentially lucrative. The graph below illustrates this roller coaster: years of R&D losses can give way to explosive growth after the approval of a single successful drug.
Overall market profit
Rigel Pharmaceuticals is a biopharmaceutical company specializing in the development of small molecules for the treatment of blood diseases and cancer. Its commercial success depends on sales of its currently approved drug and the results of new research. This graph of overall market returns reflects the investment climate, which is important for funding R&D in the biotech sector.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Rigel Pharmaceuticals
For Rigel Pharmaceuticals, which develops drugs to treat immune diseases, this chart is crucial. It reflects analysts' expectations for future revenue, which depend on the success of clinical trials, regulatory approval, and commercialization of its products. It represents the market's view of the company's scientific and commercial potential.
%20profit%20of%20the%20company%20Rigel%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Rigel-Pharmaceuticals&v=1772513618733 "Graph of future (projected) profit of the company Rigel Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma immune
Rigel Pharmaceuticals focuses on developing drugs for the treatment of immune and hematological diseases. The company's success depends on clinical trial results and regulatory approval. This chart reflects overall revenue expectations in the immunology pharmaceutical segment, allowing one to assess the investment climate in the industry and the commercialization prospects for new molecules.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772513618756 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Rigel Pharmaceuticals develops drugs to treat immune diseases. As a biotech company, its success depends more on clinical trial results and regulatory approvals than on the overall economic climate. However, a negative market outlook could complicate raising the funding needed for costly developments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513618789 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Rigel Pharmaceuticals
Rigel Pharmaceuticals develops small molecules for the treatment of immunology and oncology diseases. The company is at a stage where future success depends on clinical trial results. This chart shows how the market values its current sales in light of potential breakthroughs and future multibillion-dollar revenues from new drugs.
P/S market segment - Pharma immune
Rigel Pharmaceuticals develops small-molecule drugs for the treatment of immunology and hematology diseases. The chart shows the average revenue estimate for biotech companies. It provides insight into whether investor expectations for the commercial potential of Rigel's drugs are higher or lower than the sector average.
P/S of the market as a whole
Rigel Pharmaceuticals focuses on developing drugs to treat immune and hematological diseases. The company's success depends on clinical trial results and regulatory approval. This chart shows how the market views the biotech company's revenue, which is fraught with risks but also offers significant potential, against the backdrop of the overall economy.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Rigel Pharmaceuticals
Rigel Pharmaceuticals is a biopharmaceutical company focused on treating immune and hematological diseases. Its value is heavily dependent on the success of clinical trials and approval of new drugs. The data in the chart reflects investors' faith in Rigel's scientific potential, valuing the company based on the future sales of its promising drugs.
%20P%2FS%20Rigel%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Rigel-Pharmaceuticals&v=1772513618915 "The graph of the company's future (projected) P/S Rigel Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma immune
Rigel Pharmaceuticals focuses on developing signaling pathway inhibitors for the treatment of hematological and immune diseases. This chart shows the average estimated future sales for biotech companies in its profile. It helps understand how the market views the commercial potential of Rigel's drugs compared to expectations for its competitors' pipelines.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772513618933 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Rigel Pharmaceuticals' success in the immunology field is less dependent on overall economic sentiment, as this chart shows. Investor confidence in overall economic revenue growth has little impact on demand for life-saving medications. Rigel's key drivers are successful clinical trials and drug approvals, not the state of the business cycle.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513618941 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Rigel Pharmaceuticals
Rigel Pharmaceuticals is a biotechnology company focused on immunology and hematology. Sales of its drugs, such as TAVALISSE®, are a key source of revenue. This chart shows how successfully the company is commercializing its developments. Revenue growth reflects product acceptance by the medical community and an increasing number of patients.
Sales of companies in the market segment - Pharma immune
Rigel Pharmaceuticals develops small-molecule drugs for the treatment of immunology and hematology. Their flagship product, TAVALISSE, is designed to combat a rare blood disorder. The trend shown in this chart illustrates the overall revenue in this pharmaceutical segment, helping to understand the investment attractiveness of the entire immunology industry.
Overall market sales
Rigel Pharmaceuticals develops small-molecule drugs for the treatment of immune diseases. This chart reflects the overall health of the economy, but the pharmaceutical sector often operates by its own rules. RIGL's success depends not on consumer spending but on clinical trial results and regulatory approvals, making it unaffected by market cycles.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Rigel Pharmaceuticals
Rigel Pharmaceuticals focuses on developing kinase inhibitors for the treatment of diseases in hematology, oncology, and immunology. The company's future revenue depends on the success of clinical trials and the commercialization of its drugs. The chart shows market expectations regarding the breakthrough potential of Rigel's research.
%20sales%20of%20the%20company%20Rigel%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Rigel-Pharmaceuticals&v=1772513619048 "Schedule of future (projected) sales of the company Rigel Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma immune
Rigel Pharmaceuticals specializes in developing small molecules for the treatment of immune and hematological diseases. The company's future is closely tied to clinical trial results and regulatory approvals. This chart shows aggregate forecasts for the entire immunopharmaceuticals sector. Will Rigel's pipeline deliver superior growth?
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772513619106 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Rigel Pharmaceuticals focuses on immunology and hematology, developing drugs to treat rare diseases. The business outlook illustrated by this chart indirectly impacts the company. Sustainable economic growth ensures stable funding for healthcare systems and patient solvency, which is critical for the commercialization of expensive drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513619145 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Rigel Pharmaceuticals
Rigel Pharmaceuticals is a biopharmaceutical company focused on developing new drugs. Its financial journey involves years of investment in research, which often means negative profitability. This chart illustrates this complex journey: it shows how the company manages costs in anticipation of a breakthrough that can turn science into profit.
Market segment marginality - Pharma immune
Rigel Pharmaceuticals is a biopharmaceutical company focused on the treatment of immune and hematological diseases. This chart shows the average profitability in the pharmaceutical industry. Rigel's ability to exceed this figure is directly dependent on the commercial success of its drugs, such as Tavalisse, and the progress of clinical trials of new candidates in its pipeline.
Market marginality as a whole
Rigel Pharmaceuticals develops small-molecule drugs to treat immune diseases. The company's financial results depend on the success of clinical trials and patents, not on general economic cycles. This chart contrasts the high-risk but potentially highly profitable biotech model with the average market returns.
Employees in the company, segment and market as a whole
Number of employees in the company Rigel Pharmaceuticals
For Rigel Pharmaceuticals, a biopharmaceutical company, this chart illustrates the progress of its clinical development. An increase in this indicator often coincides with the transition of promising drugs to later, more resource-intensive phases of testing or with preparation for commercial launch, which requires the creation of a sales team. This is an indicator of the maturity of the development pipeline.
Share of the company's employees Rigel Pharmaceuticals within the market segment - Pharma immune
Rigel Pharmaceuticals focuses on developing drugs to treat complex immune and hematological diseases. It's a science-intensive business where breakthroughs are achieved by small teams of highly qualified scientists. This metric allows us to see the share of specialized researchers Rigel has in its narrow niche and assess its standing as a center of scientific expertise in the industry.
Number of employees in the market segment - Pharma immune
Rigel Pharmaceuticals is a biopharmaceutical company focused on developing signaling pathway inhibitors for the treatment of hematological and oncological diseases. The staffing changes visible in the graph are closely linked to progress in clinical trials. Hiring accelerates as drugs enter late-stage trials or are preparing for their commercial launch.
Number of employees in the market as a whole
Rigel Pharmaceuticals develops drugs to treat immune diseases. Its success is not directly linked to the overall economic situation, as reflected in this chart. The company's funding and demand for its drugs depend on the results of clinical trials and the needs of the healthcare system, not on employment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Rigel Pharmaceuticals (RIGL)
Rigel Pharmaceuticals is a biotech company whose value lies in its pipeline. This chart demonstrates that the market values scientific potential, not staff. A large portion of its capitalization, based on the promise of future drugs, is concentrated in a small team of scientists, resulting in a very high cost per employee.
%20of%20the%20company%20Rigel%20Pharmaceuticals%20(RIGL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Rigel-Pharmaceuticals-RIGL&v=1772513619292 "Chart of market capitalization per employee (in thousands of dollars) of the company Rigel Pharmaceuticals (RIGL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Rigel Pharmaceuticals focuses on developing small-molecule drugs for the treatment of hematological and immune diseases. The company's value is derived from its research and development pipeline and patent portfolio, not its headcount. This chart clearly demonstrates how the market values Rigel's research-intensive business on a per-researcher basis.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772513619304 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Rigel Pharmaceuticals focuses on developing drugs to treat immune diseases. In biopharma, a company's value lies in its research and development. This chart reflects how the market values the potential of its research portfolio. The high market capitalization per employee speaks to the value of their intellectual property and future drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513619307 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Rigel Pharmaceuticals (RIGL)
Rigel Pharmaceuticals is a biopharmaceutical company focused on immunology. Their business is a long, expensive, and risky R&D process. This chart is critical for assessing their productivity. It shows how much profit (or loss, during the research phase) each scientist and employee generates. It's a stark assessment of how effectively their intellectual capital translates into commercial success.
%20Chart%20Rigel%20Pharmaceuticals%20(RIGL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Rigel-Pharmaceuticals-RIGL&v=1772513619387 "Company Profit Per Employee (in thousands of dollars) Chart Rigel Pharmaceuticals (RIGL)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Rigel Pharma (RIGL) is an R&D biotech company (approved drug Tavalisse). This chart shows the benchmark for "Immune Pharma" (R&D). The average profit per employee in this sector (biotech) is high (if there is a hit). The benchmark reflects a "one-hit business": the sector spends millions on R&D, and a single successful orphan drug recoups all costs.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772513619405 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Rigel Pharmaceuticals is a biopharmaceutical company focused on immune and hematological diseases. Their approved drug, Tavalisse, generates revenue while the company conducts R&D on new molecules. This chart illustrates how, in biotech, financial returns per employee depend on the success of years of research and patent commercialization.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513619407 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Rigel Pharmaceuticals (RIGL)
For Rigel Pharmaceuticals, this chart reflects the financial return on intellectual capital. Here, high revenue per employee is the result of the successful commercialization of developed drugs. The dynamics demonstrate how the team of scientists and managers effectively transforms scientific breakthroughs into marketable drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Rigel-Pharmaceuticals-RIGL&v=1772513619410 "Sales chart per company employee Rigel Pharmaceuticals (RIGL)")
Sales per employee in the market segment - Pharma immune
Rigel (RIGL) is a biopharmaceutical company focused on immune diseases. They have an approved drug, Tavalisse. This chart allows us to evaluate their commercial performance. After approval, the focus shifts from R&D to sales. The success of their small sales team in generating revenue relative to personnel costs in the sector is key to their productivity.
Sales per employee for the market as a whole
Rigel is a biotech company focused on immunology. This metric demonstrates the transition from R&D to commercialization. While the company is investing in research, its research staff is large, and revenue is small. But once the drug (their "product") hits the market, this graph demonstrates how effectively a small team can generate multi-million dollar sales.
Short shares by company, segment and market as a whole
Shares shorted by company Rigel Pharmaceuticals (RIGL)
Rigel (RIGL) is a biopharmaceutical company focused on immune diseases. Their key drug, Tavalisse, treats a rare blood disorder (ITP). This chart shows the volume of bearish bets. Skeptics may doubt Tavalisse's sales potential, the success of new clinical trials, or the strength of their R&D pipeline.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Rigel-Pharmaceuticals-RIGL&v=1772513619454 "Short Shares Chart for the Company Rigel Pharmaceuticals (RIGL)")
Shares shorted by market segment - Pharma immune
Rigel Pharmaceuticals is a biopharmaceutical company focused on kinase inhibitors for the treatment of immune diseases, particularly thrombocytopenia. This chart is a barometer of sentiment across the entire biotech industry. If investors are short the sector, they don't believe in the commercial success of new drugs or expect stricter price regulations.
Shares shorted by the overall market
Rigel Pharmaceuticals (RIGL) is a biopharmaceutical company focused on immune diseases. Although they have an approved drug, they rely heavily on R&D success. This chart measures the overall level of fear. When investors panic, they avoid "risky" sectors. Biotech, which requires constant investment in research, is one of the first to be sold off, regardless of RIGL's success.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Rigel Pharmaceuticals (RIGL)
Rigel Pharmaceuticals is a biotech company balancing sales of its approved drug Tavalisse with hopes for R&D. This chart measures which side is weighing heavily in the eyes of investors. It shows when the stock is "overbought" on a strong sales report or "oversold" on news of a trial failure.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Rigel-Pharmaceuticals-RIGL&v=1772513619498 "RSI 14 indicator chart for the company's stock Rigel Pharmaceuticals (RIGL)")
RSI 14 Market Segment - Pharma immune
Rigel Pharmaceuticals is a biotech company focused on developing drugs to treat blood and immune disorders. Their lead product is approved for the treatment of immunodeficiency virus (ITP). This chart measures the overall momentum in the immunology biotech sector. It helps determine whether the entire segment is oversold based on clinical data.
RSI 14 for the overall market
Rigel Pharmaceuticals (RIGL) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RIGL (Rigel Pharmaceuticals)
Rigel Pharmaceuticals is a biotech company whose key product, Tavalisse, is approved for the treatment of a rare blood disorder (ITP). They are also exploring it for other immune disorders. This chart shows the analysts' average 12-month forecast. It reflects their assessment of Tavalisse's commercial success and the potential for further development.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RIGL-Rigel-Pharmaceuticals&v=1772513619529 "A chart showing analyst consensus forecasts for the expected stock price. RIGL (Rigel Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price RIGL (Rigel Pharmaceuticals)
Rigel (RIGL) is a biotech company focused on treating rare immune and hematological diseases. Its key approved drug is Tavalisse (for ITP, low platelet count). This chart shows the difference between the consensus estimate and the price. It reflects analyst confidence in Tavalisse's growth and the company's R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RIGL-Rigel-Pharmaceuticals&v=1772513619530 "A chart showing the difference between the consensus forecast and the actual stock price. RIGL (Rigel Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Rigel Pharmaceuticals (RIGL) is a biotech company whose commercial product, Tavalisse, treats a rare blood disorder (ITP). The company is also developing an oncology pipeline. This chart shows general expectations for the immunotherapy sector. It reflects whether experts believe Tavalisse's R&D and sales growth will be successful.
Analysts' consensus forecast for the overall market share price
Rigel Pharmaceuticals (RIGL) is an R&D biotech with one approved product (Tavalisse) for a rare blood disorder. This chart, reflecting the economic consensus, reflects their risk appetite. During a downturn (pessimism), investors flee cash-burning biotechs (on R&D), fearing competition.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Rigel Pharmaceuticals
Rigel is a biotech company with a commercial product. Their flagship drug, Tavalisse, is approved for the treatment of a rare blood disorder (ITP). They aim to expand its use. This chart is a commercialization indicator. It likely aggregates the sales growth rate of their drug and the market's assessment of their R&D pipeline, which should lead to new indications.
AKIMA Market Segment Index - Pharma immune
Rigel (RIGL) is a commercial biotech focused on immunology and hematology; the company owns the approved drug Tavalisse (for the treatment of the rare blood disorder ITP). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this niche commercial model (RIGL) differentiate it from the average pharma company?
The AKIM Index for the overall market
Rigel Pharmaceuticals is a biotech company commercializing Tavalisse (immune thrombocytopenia) and Rezlidhia (leukemia). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this profit-seeking commercial company stacks up against the broader economic trends affecting the healthcare sector.
